• Users Online: 122
  • Print this page
  • Email this page

 
Table of Contents
SPECIAL ARTICLE
Year : 2021  |  Volume : 15  |  Issue : 1  |  Page : 1-3

NOTTO COVID-19 vaccine guidelines for transplant recipients


1 Department of Nephrology, Institute of Kidney Diseases and Research Center; Dr. H L Trivedi Institute of Transplantation Sciences (IKDRC-ITS), Ahmedabad, Gujarat; Secretary, Indian Society of Organ Transplantation (ISOT), Delhi, India
2 Department of Nephrology, All India Institute of Medical Sciences, Delhi, India
3 Former Professor and Head Nephrology, Banaras Hindu University, Varanasi, Uttar Pradesh; President, Indian Society of Organ Transplantation (ISOT), Delhi, India
4 Department of Transplantation Surgery, Apollo Hospital; Past President, Indian Society of Organ Transplantation (ISOT), Delhi, India
5 Managing Trustee, MOHAN Foundation, Chennai, Tamil Nadu; President-Elect, Indian Society of Organ Transplantation (ISOT), Delhi, India
6 Department of Transplant Surgery, The Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India
7 Department of Nephrology, Venkateshwar Hospital, Delhi, India
8 Department of Nephrology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
9 Department of Nephrology, Osmania Medical College, Hyderabad, Telangana, India
10 Department of Liver Transplant Surgery, Max Center of Liver and Biliary Sciences at Max Hospital, Saket, Delhi; Past President, Liver Transplant Society of India (LTSI), Kochi, Kerala, India
11 Clinical Professor in Transplantation and Gastrointestinal Surgery, Amrita Institute of Medical Sciences and Research Centre, Kochi, Kerala; President, Department of Cardiovascular Surgery Max Super Specialty Hospital, Saket, New Delhi, India
12 Department of Cardiovascular Surgery Max Super Specialty Hospital, Saket, New Delhi; President, Indian Society for Heart and Lung Transplantation, Delhi, India
13 Director, National Organ and Tissue Transplant Organization, Delhi, India
14 Director General of Health Services, Delhi, India

Date of Submission22-Jan-2021
Date of Acceptance01-Mar-2021
Date of Web Publication31-Mar-2021

Correspondence Address:
Dr. Vasanthi Ramesh
Director, National Organ and Tissue Transplant Organization, 4th Floor, National Institute of Pathology, NIOP Building, Safdarjung Hospital Campus, New Delhi - 110 029
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijot.ijot_2_21

Get Permissions

  Abstract 


In December 2019 Novel corona virus (SARS-CoV-2) infection started in Wuhan and resulted in a pandemic within few weeks' time. Organ transplant recipients being at a risk for more severe COVID-19 if they get SARS CoV-2 viral infection, COVID 19 Vaccine has a significant role in these patients. The vaccine is a safer way to help build protection and would either prevent COVID -19 infection or atleast diminish the severity of the disease. It would also reduce the risk of the continuing transmission and enhance herd immunity. Immuno compromised patients should not receive live vaccines as they can cause vaccine related disease and hence the guidelines suggest that all transplant recipients should receive age appropriate 'inactivated vaccine' as recommended for general population. Though trials have not been undertaken on transplant recipients, efficacy and safety of COVID-19 vaccine have been scientifically documented for few vaccines among the general population.

Keywords: NOTTO, COVID 19 vaccine, Guidelines, transplant recipients


How to cite this article:
Kute V, Agarwal SK, Prakash J, Guleria S, Shroff S, Sharma A, Varma P, Prasad N, Sahay M, Gupta S, Sudhindran S, Krishan K, Ramesh V, Kumar S. NOTTO COVID-19 vaccine guidelines for transplant recipients. Indian J Transplant 2021;15:1-3

How to cite this URL:
Kute V, Agarwal SK, Prakash J, Guleria S, Shroff S, Sharma A, Varma P, Prasad N, Sahay M, Gupta S, Sudhindran S, Krishan K, Ramesh V, Kumar S. NOTTO COVID-19 vaccine guidelines for transplant recipients. Indian J Transplant [serial online] 2021 [cited 2021 Apr 11];15:1-3. Available from: https://www.ijtonline.in/text.asp?2021/15/1/1/312748




  Introduction Top


With the use of COVID-19 appropriate behavior, in many countries, the incidence of COVID-19 is decreasing, though not with the same degree in every country. With the development of a safe vaccine against COVID-19, its global utilization is paramount. Transplant recipients being a high-risk group for COVID-19 infection, these vaccines are urgently required for these patients. The Centers for Disease Control and Prevention suggest that COVID-19 vaccination will help in the prevention of COVID-19, is a safer way to help build protection, and will be an important tool to help in stopping ongoing pandemic.[1]

Advantages of getting a COVID-19 vaccine[1],[2],[3],[4],[5],[6]

  1. Risk of acquiring COVID-19 infection goes down substantially
  2. Risk of having severe COVID disease even if one acquires the infection is substantially reduced
  3. The risk of continuing transmission to others will decrease
  4. Vaccine will help in the faster development of herd immunity.



  Rationale and General Principle for the Vaccination Top


Severe acute respiratory syndrome coronavirus 2 (SARS-Cov2) infection has significantly impacted transplant recipients, with high morbidity and mortality (5%–35%).[7],[8],[9] Vaccination for these high-risk patients is a priority.

  1. Patients with immunosuppression may have reduced response to vaccination because of altered T-lymphocyte functions. These patients may have lower antibody responses compared to the general population. Antibody response usually correlates with the degree of immunosuppression
  2. In general, in immunocompromised patients, live vaccines can cause vaccine-related disease; therefore, patients with organ transplants should not receive live vaccines.[10],[11],[12] Kidney Disease: Improving Global Outcomes and American Society of Transplantation-Infectious Disease Community of Practice guidelines suggest that all transplant recipients should receive age-appropriate “inactivated vaccine” as recommended for the general population[13],[14]
  3. Efficacy and safety of COVID-19 vaccine have been scientifically documented only for few vaccines and many are still under clinical trial.[15],[16],[17],[18] Initial trial of COVID-19 vaccine had included healthy volunteers, and patients with comorbidity but trials on transplant recipients have not been done till the publication of these guidelines
  4. Participating recipients can have minor side effects as seen in many other vaccines such as vaccine site pain, fever, fatigue, muscle and joint pain, and headache after administration of COVID-19 vaccine. These side effects do not mean vaccines are unsafe. Severe or long-lasting side effects are extremely rare. In addition, COVID-19 vaccines are continuously being monitored for safety in postmarketing surveys to detect rare adverse events
  5. In cases of any adverse event, the transplant patient is required to report to health-care providers for appropriate management. After the completion of COVID-19 schedule, routine antibody testing is not required to confirm seroconversion. If needed for research, antibody testing can be done after 14 days of the second dose
  6. More studies are required to document energy, duration of immunity, and requirement of a booster dose in case no antibodies develop. [Table 1] shows details of few common regulatory bodies' approved COVID-19 vaccine.
Table 1: Types of COVID-19 vaccines

Click here to view



  COVID-19 Vaccine Guidelines Top


  1. We recommend that all transplant team members should support and encourage appropriate uptake of vaccine by counseling transplant recipients and addressing vaccine hesitancy
  2. We recommend using virtual platforms for information related to COVID-19 vaccine for all transplant team members, who are a major source of information for the transplant recipient community
  3. Based on other vaccine guidelines for solid organ transplant recipients,[11],[12],[13],[14],[15] we suggest that transplant recipients and their household members should get vaccinated against any COVID-19 vaccine that is authorized or approved by their health regulators/agencies. Transplant recipients scheduled for transplantation should be given vaccine 2 weeks prior to surgery or 1 to 6 month posttransplant.[13],[14] Even after vaccination, COVID-19 appropriate behaviors such as wearing face mask, hand hygiene, cough etiquettes, and social distancing should be continued by all recipients
  4. Transplant recipients who have previous COVID-19 infection and or have antibodies against COVID-19 are also required to be vaccinated. There is no need of testing for antibodies against coronavirus before giving COVID-19 vaccination. Transplant recipients should undergo an entire schedule of vaccination with only one type of vaccine and different COVID-19 vaccines should not be used in the same patient. In case, a transplant recipient misses the second dose of COVID-19 vaccine at the scheduled time, then the second dose is to be given as early as possible. Revaccination is not required
  5. Transplant patients with suspected or active SARS-Cov2 infection should not get the vaccination. Vaccination should be deferred for 4–8 weeks after symptom resolution
  6. Please see the details of COVID-19 vaccine operational guidelines updated as of December 28, 2020.[2],[3],[22]


Disclaimer: COVID-19 pandemic is evolving in a dynamic manner, therefore, this COVID-19 vaccine Guideline is a live and dynamic document and will be updated as per the evolving situation. This is consensus Guidelines of National Organ and Tissue Transplant OrganisationIndian society of Organ Transplantation, Liver Transplant Society of India and Indian Society for Heart and Lung Transplantation as on January 19, 2021.

Note: This special article is being published simultaneously in the Indian Journal of Transplantation and the Indian Journal of Nephrology, as per the decision of Editor-In-Chiefs of both these journals.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
  References Top

1.
Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/vaccine-benefits.html. [Last accessed on 2021 Jan 14].  Back to cited text no. 1
    
2.
Available from: https://www.mohfw.gov.in/pdf/COVID19VaccineOG111 Chapter 16.pdf. [Last accessed on 2021 Jan 14].  Back to cited text no. 2
    
3.
Available from: https://www.mohfw.gov.in/pdf/Covid19Communication Strategy2020.pdf. [Last accessed on 2021 Jan 14].  Back to cited text no. 3
    
4.
American Society of Transplantation, Transplant Capacity and Early Vaccine Recommendations. Available from: https://www.myast.org/sites/default/files/2020%2012%2008%20COVID19%20VACCINE%20FAQS_FINAL.pdf. [Last accessed on 2021 Jan 14].  Back to cited text no. 4
    
5.
COVID-19 Vaccination for Adult Patients with Kidney Disease: A Position Statement from the UK Renal Community. Available from: https://britishrenal.org/covid-19-vaccination-for-adult-patients-with-kidney-disease/. [Last accessed on 2021 Jan 14].  Back to cited text no. 5
    
6.
Guidance from the International Society of Heart and Lung Transplantation Regarding the SARS CoV-2 Pandemic. Available from: https://ishlt.org/ishlt/media/documents/SARS-CoV-2_Guidance-for-Cardiothoracic-Transplant-and-VAD-center.pdf. [Last accessed on 2021 Jan 14].  Back to cited text no. 6
    
7.
Taking Immunosuppressants? Fauci Says Get the COVID-19 Vaccine. Available from: https://www.ajmc.com/view/taking-immunosuppressants-fauci-says-get-the-covid-19-vaccine. [Last accessed on 2021 Jan 14].  Back to cited text no. 7
    
8.
Kute VB, Bhalla AK, Guleria S, Ray DS, Bahadur MM, Shingare A, et al. Clinical profile and outcome of COVID-19 in 250 kidney transplant recipients: A multicenter cohort study from India. Transplantation 2020;Publish Ahead of Print. doi: 10.1097/TP.0000000000003593. Online ahead of print.  Back to cited text no. 8
    
9.
Raja MA, Mendoza MA, Villavicencio A, Anjan S, Reynolds JM, Kittipibul V, et al. COVID-19 in solid organ transplant recipients: A systematic review and meta-analysis of current literature. Transplant Rev (Orlando) 2021;35:100588.  Back to cited text no. 9
    
10.
Craig-Schapiro R, Salinas T, Lubetzky M, Abel BT, Sultan S, Lee JR, et al. COVID-19 outcomes in patients waitlisted for kidney transplantation and kidney transplant recipients. Am J Transplant 2020. doi: 10.1111/ajt.16351. Epub ahead of print. PMID: 33043597; PMCID: PMC7675359.  Back to cited text no. 10
    
11.
Guidelines for vaccination in kidney transplant recipients. Indian J Nephrol 2016;26 Suppl S1:19-25.  Back to cited text no. 11
    
12.
Stucchi RSB, Lopes MH, Kumar D, Manuel O. Vaccine recommendations for solid-organ transplant recipients and donors. Transplantation 2018;102:S72-80.  Back to cited text no. 12
    
13.
Cordonnier C, Einarsdottir S, Cesaro S, Di Blasi R, Mikulska M, Rieger C, et al. Vaccination of haemopoietic stem cell transplant recipients: Guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis 2019;19:e200-12.  Back to cited text no. 13
    
14.
Summary of Recommendation for Vaccination in Kidney Transplants. Available from: https://kdigo.org/wp-content/uploads/2018/08/KDIGO-Txp-Candidate-GL-FINAL.pdf. [Last accessed on 2021 Jan 14].  Back to cited text no. 14
    
15.
Danziger-Isakov L, Kumar D, AST ID Community of Practice. Vaccination of solid organ transplant candidates and recipients: Guidelines from the American society of transplantation infectious diseases community of practice. Clin Transplant 2019;33:e13563.  Back to cited text no. 15
    
16.
Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 2020;383:2603-15.  Back to cited text no. 16
    
17.
Safety and Immunogenicity Clinical Trial of an Inactivated SARS-CoV-2 Vaccine, BBV152. Available from: https://clinicaltrials.gov/ct2/show/NCT04471519. [Last accessed on 2021 Jan 14].  Back to cited text no. 17
    
18.
Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): A single-blind, randomised, controlled, phase 2/3 trial. Lancet 2021;396:1979-93.  Back to cited text no. 18
    
19.
The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Moderna COVID-19 Vaccine — United States, December 2020. Available from: https://www.cdc.gov/mmwr/volumes/69/wr/mm695152e1.htm. [Last accessed on 2021 Jan 14].  Back to cited text no. 19
    
20.
Press Statement by the Drugs Controller General of India (DCGI) on Restricted Emergency Approval of COVID-19 Virus Vaccine. Available from: https://pib.gov.in/PressReleseDetail.aspx?PRID=1685761. [Last accessed on 2021 Jan 14].  Back to cited text no. 20
    
21.
Ministry of Health and Family Welfare Guidelines for Vaccination in COVID19. Available from: https://www.mohfw.gov.in. [Last accessed on 2021 Jan 14].  Back to cited text no. 21
    
22.



 
 
    Tables

  [Table 1]



 

Top
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
Abstract
Introduction
Rationale and Ge...
COVID-19 Vaccine...
References
Article Tables

 Article Access Statistics
    Viewed556    
    Printed4    
    Emailed0    
    PDF Downloaded80    
    Comments [Add]    

Recommend this journal